Efficacy of acupoint application in patients with overactive bladder: A randomized, placebo-controlled pilot trial

被引:0
|
作者
Tang, Heshu [1 ]
Zhu, Chunqin [2 ]
Xu, Suping [1 ]
Wang, Yan [1 ]
Gao, Juanjuan [1 ]
Zhou, Ping [1 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Dept Neurol, 155 Hanzhong Rd, Nanjing 210029, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Nursing, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China
关键词
Overactive bladder; Acupoint application; Traditional Chinese medicine; OABSS; NGF; NERVE GROWTH-FACTOR; QUALITY-OF-LIFE; SYMPTOM; WOMEN;
D O I
10.1016/j.explore.2023.03.009
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Conventional treatments for alleviating the symptoms of Overactive bladder (OAB) have been reported to have limited efficacy and a high rate of side effects. Traditional Chinese medicine (TCM) has been used in Asia countries because of its low side effects and being easy to operate. To confirm the efficacy of acupoint application treatment for alleviating OAB symptoms, a randomized and placebo-controlled pilot trial was conducted in this study.Methods: All participants were randomly allocated into a treatment group or control group, receiving either a "Dinggui" acupoint application or placebo treatment for 4 weeks. The outcome measures were OAB symptom scores (OABSS), OAB questionnaire (OAB-q) scores, and TCM syndrome scores. Urine nerve growth factor (NGF) level, NGF normalized to urine creatinine (NGF/Cr), and maximum flow rate (Qmax) were also measured to evaluate the OAB symptoms. Results: In total, 69 participants were included with 34 in the treatment group and 35 in the placebo-treated group. Treatment with "Dinggui" acupoint application showed a statistically significant decrease in OABSS scores (8.10 & PLUSMN;1.54 to 3.67 & PLUSMN;1.77), OAB-q scores (61.43 & PLUSMN;13.93 to 38.13 & PLUSMN;15.42), and TCM syndrome scores (15.60 & PLUSMN;5.98 to 9.20 & PLUSMN;4.82). The NGF and NGF/Cr were also observed meaningful changes in a decrease from 379.68 to 136.17 pg/ml and from 0.30 to 0.16 pg/mg, respectively. The Qmax value showed a significant increase from 14.40 to 24.05 ml/s.Conclusions: Treatment with "Dinggui" acupoint application could be considered an effective and alternative therapy for OAB management. Further studies with larger sample sizes and longer treatment periods are needed to investigate.
引用
收藏
页码:749 / 754
页数:6
相关论文
共 50 条
  • [1] A multicenter, randomized, placebo-controlled trial of trospium chloride in overactive bladder patients
    Rudy, D
    Cline, K
    Goldberg, K
    Harris, R
    [J]. NEUROUROLOGY AND URODYNAMICS, 2004, 23 (5-6) : 600 - 601
  • [2] Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial
    Gotoh, Momokazu
    Yokoyama, Osamu
    Nishizawa, Osamu
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2011, 18 (05) : 365 - 373
  • [3] A randomized placebo-controlled study of the efficacy of antimuscarinics in the treatment of pediatric overactive bladder and incontinence
    Steve J. Hodges
    Anthony Atala
    [J]. Current Urology Reports, 2009, 10 (1) : 6 - 7
  • [4] Efficacy of cinnamon patch treatment for alleviating symptoms of overactive bladder: A double-blind, randomized, placebo-controlled trial
    Chen, Lih-Lian
    Shen, Yuh-Chiang
    Ke, Chih-Chun
    Imtiyaz, Zuha
    Chen, Hui-, I
    Chang, Chin-Hsien
    Lee, Mei-Hsien
    [J]. PHYTOMEDICINE, 2021, 80
  • [5] Pilot efficacy and tolerability: A randomized, placebo-controlled trial of levetiracetam for essential tremor
    Handforth, A
    Martin, FC
    [J]. MOVEMENT DISORDERS, 2004, 19 (10) : 1215 - 1221
  • [6] Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial
    Chen, Hongde
    Wang, Feng
    Yu, Zhixian
    Zhang, Yirong
    Liu, Chaohui
    Dai, Shengjie
    Chen, Bicheng
    Lv, Jiaju
    [J]. UROLOGY, 2017, 100 : 59 - 64
  • [7] Hypnotherapy for Treatment of Overactive Bladder: A Randomized Controlled Trial Pilot Study
    Komesu, Yuko M.
    Sapien, Robert E.
    Rogers, Rebecca G.
    Ketai, Loren H.
    [J]. FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2011, 17 (06): : 308 - 313
  • [8] A Prospective, Randomized, Placebo-Controlled Pilot Study of Mirabegron (Myrbetriq®) and Behavioral Modification for Overactive Bladder in Parkinson Disease
    Agarwal, Pinky
    Brown, Theodore
    Ray, Sudeshna
    Madan, Arina
    Roy-Faderman, Ina
    Burdick, Daniel
    [J]. NEUROLOGY, 2020, 94 (15)
  • [9] A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan
    Chuang, Yao-Chi
    Lin, Chih-Chieh
    Chow, Po-Ming
    Lien, Chi-Shun
    Tsui, Ke-Hung
    Chou, Chieh-Lung
    Lee, Hsiang-Ying
    Meng, En
    Kuo, Hann-Chorng
    [J]. LUTS-LOWER URINARY TRACT SYMPTOMS, 2021, 13 (01) : 108 - 117
  • [10] MIRABEGRON FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE: A DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Cho, Sung Yong
    Jeong, Jin
    Kim, Janghwan
    Lee, Seong Ho
    Lee, Sangchul
    Choo, Min Soo
    Oh, Seung-June
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E1023 - E1023